Exclusive: Three Hepatitis C Drugs from Foreign Pharmaceuticals Close to Approval, Sources Say
(Beijing) — Three hepatitis C drugs from American pharmaceutical giants Johnson & Johnson and Bristol-Myers Squibb (BMS) that could cut treatment time in half will soon be available to Chinese patients, sources from the country’s food and drug authority said.
China Food and Drug Administration has already completed the technical evaluations and is reviewing data from clinic trials, after which the three drugs — simeprevir, asunaprevir and daclatasvir — will be allowed in the market, CFDA sources told Caixin.
The drug simeprevir is made by Johnson & Johnson, while the other two are supplied by BMS.
There are at least 130 million people globally who are suffering from chronic hepatitis C, according to the World Health Organization (WHO). In China, the figure is about 10 million, said Zhang Hong, director of the infectious-diseases department at Shaanxi Provincial People’s Hospital, the Shaanxi-based newspaper Chinese Business View reported.
A significant number of those who are chronically infected will develop liver cirrhosis or liver cancer, according to WHO.
China still uses old-generation therapies based on two drugs, interferon and ribavirin, which require weekly injections for up to 48 weeks and cure approximately half of the treated patients. They are also known for harsh side effects such as headaches and hair loss.
Another safer and more-effective group of drugs, known as direct antiviral agents (DAAs), wasn’t widely recognized until 2013 when the U.S. Food and Drug Administration approved sofosbuvir to be used in hepatitis C treatment. Simeprevir, asunaprevir and daclatasvir belong to this DAA category.
DAA drugs ensure that in over 90% of patients treated for serious chronic hepatitis C infections, the virus will not reappear for 12 weeks or more after completing the therapy, which signals complete recovery, according to CFDA sources. The drugs can also cut down treatment time by half, to 24 weeks.
Since 2013, DAAs have become very popular, and their global sales have jumped from $5 billion in 2013 to $24 billion in 2015, according to pharmaceutical and biotechnology research firm EvaluatePharma.
But China delayed adopting the latest treatments until 2015 when the State Council, China’s cabinet, promised to accelerate the evaluation of certain medicines, including the three hepatitis C drugs mentioned above, as well as some other hepatitis C drugs produced by other foreign and Chinese firms.
As the drugs are slated to hit the market soon, their hefty prices have raised concerns among patient groups.
DAAs are costlier than the alternatives. In the U.S., it costs $70,000 to $140,000 for up to 48 weeks of treatment using this category of medicine. In Japan, the expense is about 3 million yen ($27,000) for a comparable course of drugs.
The pharmaceutical companies haven’t yet revealed the prices of the drugs for the Chinese market.
Contact reporter Coco Feng (email@example.com)
Sep 17 17:56
Sep 17 15:30
Sep 17 14:59
Sep 17 12:13
Sep 17 05:10
Sep 17 05:10
- 1Update: China Ditches Caps on Foreign Institutional Investor Programs
- 2Chinese Banks Told to Curb Loans to Developers, Homebuyers
- 3Alibaba Begins a New Era After Jack Ma’s Retirement
- 4Update: China’s Economic Activity Slowed Further in August
- 5LGFV Under Financial Pressure Skips Call Option on Yuan Bond
- 1Power To The People: Pintec Serves A Booming Consumer Class
- 2Largest hotel group in Europe accepts UnionPay
- 3UnionPay mobile QuickPass debuts in Hong Kong
- 4UnionPay International launches premium catering privilege U Dining Collection
- 5UnionPay International’s U Plan has covered over 1600 stores overseas